急性侵袭性曲霉病何时更换治疗:专家观点
侵袭性曲霉病(IA)多见于因恶性肿瘤化疗、移植或自身免疫病使用免疫抑制剂而免疫受损的患者。一个专家咨询委员会制定了一套用于临床试验设计、也可用于临床实践的IA管理标准,明确了原发性抗真菌治疗失败时更换治疗的时机。
要点
- 确认感染部位分离出对一线药物耐药菌株或分子检测发现耐药突变时应更换治疗。
- 一线治疗第8天或之后出现半乳甘露聚糖升高/新阳性、临床突然恶化或新感染灶时应更换。
- 一线治疗第15天或之后临床稳定但半乳甘露聚糖持续升高或影像病灶增大>25%时应更换。
核心结论
- 专家咨询委员会提出了原发性抗真菌治疗失败时更换治疗的时机标准,可用于临床试验设计及临床实践。
研究设计与样本
- 专家咨询委员会制定管理标准,未报告系统检索方法或样本量。
主要发现
- 原发性治疗失败更换治疗的时机包括耐药证据、治疗第8天或之后特定临床/微生物学恶化、以及治疗第15天或之后稳定但持续抗原升高或影像进展。
关键数值与推荐
- 确认感染部位分离出对一线药物耐药菌株或分子检测发现耐药突变时应更换治疗。
- 一线治疗第8天或之后出现血清半乳甘露聚糖升高或新阳性(血清或BALF)、临床突然恶化或新感染灶时应更换。
- 一线治疗第15天或之后临床稳定但≥2次血清半乳甘露聚糖持续高于基线或升高,或CT/其他影像原病灶增大>25%且免疫状态无变化时应更换。
临床怎么用
- 临床可参照上述时机评估原发性抗真菌治疗失败并决定是否更换方案。
局限性
- 原文未报告证据等级、推荐强度或验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.
引用
- Slavin MA, Chen YC, Cordonnier C, et al. When to change treatment of acute invasive aspergillosis: an expert viewpoint. J Antimicrob Chemother. 2021. PMID: 34508633. doi:10.1093/jac/dkab317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。